- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07629973
A Study of the Determinants of Neurological Outcomes in Patients With Acute Respiratory Distress Syndrome (NEURDS)
Etude Des déterminants de l'évolution NEUrologique Des Patients Ayant présenté un Syndrome de Détresse Respiratoire aiguë
Acute respiratory distress syndrome (ARDS) is characterized by pathological pulmonary edema caused by direct or indirect damage to the alveolar-capillary membrane.
Its management relies on etiological treatment, invasive mechanical ventilation, and the use of sedatives and neuromuscular blockers, depending on the patient's condition.
Improvements in patient care have led to an improved prognosis. However, in-hospital mortality remains high (between 35% and 45%). Notably, morbidity among surviving patients is very high and is largely dominated by neuropsychological sequelae. Attention and executive function disorders, confusion, disorientation, or memory impairment are thus found in 70 to 100% of patients following ARDS. These disorders are still present in 46 to 80% of surviving patients one year after ARDS and in 20% of them five years later.
Although essential to treatment, mechanical ventilation carries a risk of significant complications. Beyond the risk of infection and complications related to sedation and neuromuscular blockade, the use of mechanical ventilation is associated with a risk of ventilator-induced lung injury (VILI).
The use of so-called protective ventilation reduces the risk of VILI and improves patient outcomes. However, analysis of relevant physiological parameters shows that the risk of VILI may still exist even when ventilator settings comply with recommendations and the concept of protective ventilation. Driving pressure (which represents Strain) is a good marker of VILI; it represents the distension of the lung with each breath relative to the initial lung volume. Values above 14 cmH₂O are associated with high mortality in patients with ARDS. Inspiratory transpulmonary pressure represents Stress-that is, the pressure that distends the alveoli at the end of inspiration-and is also associated with the risk of VILI. Finally, mechanical power represents the amount of energy delivered to the lung by the ventilator and has been validated as a marker of VILI. The advantage of mechanical power over the other indices described is that it incorporates all components that can lead to VILI.
Among the various sources of neurological damage during ARDS, inflammatory processes appear to play a major role. Numerous inflammatory mediators (TNF-α, IL-6, IL-8, IL-1β) are secreted during ARDS, and animal studies have demonstrated a link between inflammation and hippocampal damage. Furthermore, cerebral ischemic lesions, exacerbated by systemic inflammation and endothelial activation leading to coagulation activation with thrombus formation, may also contribute to the development of cognitive impairments.
In addition to the inflammatory processes associated with ARDS, mechanical ventilation itself may have a significant impact on neuroinflammatory damage. Recently, the term "ventilator-associated brain injury" (VABI) has been proposed to describe these secondary neurological lesions induced by mechanical ventilation. Studies in mouse and pig models have demonstrated a relationship between the dose and duration of VILI, apoptosis, neuroinflammation, and neuronal damage. An animal study in mice also showed an association between the duration of mechanical ventilation and the onset of cognitive impairments.
During brain injury, proteins and neurotransmitters are released and serve as biomarkers of brain damage. Elevated plasma levels of S100B protein indicate astrocyte damage caused by traumatic, anoxic-ischemic, or inflammatory mechanisms. It correlates with neurological prognosis following cardiac arrest, in ischemic or hemorrhagic strokes, in neurodegenerative diseases, and in patients with traumatic brain injury.
Clinical studies have shown a negative correlation between elevated S100B protein levels, the MoCA score, and the MMSE in patients with OSA or COPD, respectively, indicating an association between this protein and cognitive impairment.
We therefore hypothesize that mechanical ventilation associated with high mechanical power is linked to a significant risk of brain injury, reflected by elevated serum S100B protein levels and the presence of neurocognitive disorders long after ARDS.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: François Beloncle, Professor
- Número de telefone: +33 2 41 35 38 15
- E-mail: Francois.Beloncle@chu-angers.fr
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Adult patient
- Patient admitted to the intensive care unit less than 48 hours ago
Patient diagnosed with mild, moderate or severe ARDS according to the Berlin classification based on the PaO₂/FiO₂ ratio, with a minimum PEEP set at 5 cmH₂O (16), of pulmonary aetiology:
- Mild ARDS: 200 < PaO₂/FiO₂ < 300 mmHg
- Moderate ARDS: 100 < PaO₂/FiO₂ < 200 mmHg
- Severe ARDS: PaO₂/FiO₂ < 100 mmHg
- Patients fitted with an oesophageal pressure measurement catheter (Nutrivent, Sidam, San Giacomo Roncole, Italy)
- Patients registered with or covered by a social security scheme
- Free and informed consent from the patient or a trusted relative (where the patient is unable to give consent).
Exclusion Criteria:
Patients with a history of central nervous system disorders resulting in cognitive impairment
- Patients on ECMO
- Patients admitted for symptomatic central nervous system disorders
- Patients admitted for acute respiratory distress syndrome following cardiorespiratory arrest.
- Patients being treated for a psychiatric condition, chronic heavy drinkers, or those undergoing long-term treatment with benzodiazepines, antidepressants or antipsychotics.
- Pregnant, breastfeeding or labouring patients
- Individuals subject to a legal protection order
- Individuals receiving compulsory psychiatric care
- Individuals deprived of their liberty by judicial or administrative decision
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Exploratory arm
collection of oesophageal pressure data, mechanical power calculation, MOCA score collection and blood sample collection for S100B protein dosage
|
collection of oesophageal pressure data, mechanical power calculation, MOCA score collection and blood sample collection for S100B protein dosage
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
to determine whether there is an association between the mechanical power between Day 1 and Day 3 (reflecting the risk of VILI)
Prazo: at day 1, day 2 and day 3
|
mechanical power calculation
|
at day 1, day 2 and day 3
|
|
to determine serum S-100B protein level between Day 1 (H0) and Day 3 (H72).
Prazo: at day 1, day 2 and day 3
|
S-100B protein dosage
|
at day 1, day 2 and day 3
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To investigate the association between serum S100B protein concentrations from day 1 to day 3 and neurological outcome at 3 months and 12 months
Prazo: at 3 and 12 months
|
Correlation coefficient between S-100B protein levels from Day 1 to Day 3 and the MOCA score at 3 and 12 months (no neurocognitive impairment if MOCA ≥ 26/30, neurocognitive impairment if < 25/30).
|
at 3 and 12 months
|
|
To investigate the association between other VILI markers (inspiratory transpulmonary pressure and driving pressure) and serum S100B protein concentrations from day 1 to day 3.
Prazo: From day 1 to day 3
|
Correlation coefficient between inspiratory transpulmonary pressure and driving pressure, and serum S-100B levels between Day 1 and Day 3, whilst accounting for potential confounding factors in a multivariate model
|
From day 1 to day 3
|
|
To investigate the association between these other VILI markers and neurological outcomes at 3 months and 12 months.
Prazo: at 3 and 12 months
|
Correlation coefficient between mechanical power, inspiratory transpulmonary pressure and driving pressure (average of values measured between J1 and J3) and the MOCA score at 3 and 12 months, taking potential confounding factors into account in a multivariate model
|
at 3 and 12 months
|
|
To investigate the association between the occurrence of delirium during a stay in the intensive care unit and neurological outcomes at 3 and 12 months.
Prazo: at 3 and 12 months
|
The occurrence of neurocognitive impairment, defined as a MoCA score of <25/30 at the 3- and 12-month assessments, in patients who experienced delirium in the intensive care unit compared with those who did not.
|
at 3 and 12 months
|
|
Describe the prevalence of depression (PHQ-9 score) among patients who presented ARDS
Prazo: at 3 months
|
occurrence of depressive symptoms (defined as a PHQ-9 score > 10)
|
at 3 months
|
|
Describe the prevalence of post-traumatic stress (PCL-5 score) among patients who presented ARDS
Prazo: at 3 months
|
occurrence of post-traumatic stress (defined as a PCL-5 score > 33)
|
at 3 months
|
|
Describe the prevalence of anxiety (GAD-2 score) among patients who presented ARDS
Prazo: at 3 months
|
anxiety disorders (defined as a GAD-2 score > 3)
|
at 3 months
|
|
Describe the decline in quality of life (Euro 5d 5l score) among patients who presented ARDS
Prazo: at 3 months
|
deterioration in quality of life (EuroQol-5D-5L score analysed both continuously and categorically)
|
at 3 months
|
|
Describe the prevalence of independence (IADL) among patients who presented ARDS
Prazo: at 3 months
|
occurence of a decline in functional independence (defined as the loss of at least one instrumental activity compared with the level prior to hospitalisation)
|
at 3 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 49RC25_0292
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Blood test scores calculations
-
MicroPhage, Inc.ConcluídoSepse | Bacteremia | Infecção | Infecção EstafilocócicaEstados Unidos